Respiratory syncytial virus prophylaxis in a tertiary care neonatal intensive care unit

Pediatr Infect Dis J. 2009 Sep;28(9):842-4. doi: 10.1097/INF.0b013e3181a0ad01.


Nosocomial transmission of respiratory syncytial virus (RSV) is a serious, preventable cause of RSV infection. Passive RSV prophylaxis became available in 1996. We compared the RSV nosocomial infection rate in our neonatal intensive care unit before and after RSV prophylaxis, using nosocomial rotavirus infections as a comparator. There were no significant differences between nosocomial RSV infection rates before and after institution of prophylaxis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Viral / therapeutic use*
  • Chemoprevention / methods*
  • Cross Infection / epidemiology
  • Cross Infection / prevention & control*
  • Humans
  • Infant
  • Infant, Newborn
  • Intensive Care, Neonatal*
  • Palivizumab
  • Prevalence
  • Respiratory Syncytial Virus Infections / epidemiology
  • Respiratory Syncytial Virus Infections / prevention & control*


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Viral
  • Palivizumab